GenVec, Inc.
(NASDAQ : GNVC)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Bitcoin & Crypto Movers
Receive our Bitcoin / Cryptocurrency Reports, Free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Major
symbolcompany%chnglast%shortavg$volume
JNJJohnson & Johnson
-0.06%125.870.6%$873.95m
PFEPfizer Inc.
-0.11%37.320.9%$678.99m
ABBVAbbVie, Inc.
-1.16%88.912.1%$588.97m
MRKMerck & Co., Inc.
0.02%62.520.6%$527.86m
BMYBristol-Myers Squibb Company
0.32%56.721.4%$314.96m
LLYEli Lilly and Company
-1.05%88.491.0%$253.24m
NVSNovartis AG Sponsored ADR
1.84%82.290.2%$188.53m
AZNAstraZeneca PLC Sponsored ADR
0.39%37.181.3%$135.85m
GSKGlaxoSmithKline plc Sponsored ADR
2.90%41.870.2%$105.42m
SNYSanofi Sponsored ADR
1.12%42.380.2%$102.48m
NVONovo Nordisk A/S Sponsored ADR Class B
1.24%50.430.1%$78.67m
LCILannett Company, Inc.
-3.13%12.4037.9%$7.01m
AKTXAkari Therapeutics Plc Sponsored ADR
0.97%2.081.7%$0.20m
EPIXESSA Pharma Inc
-3.53%3.550.0%$0.03m

Company Profile

GenVec, Inc. is a clinical-stage gene delivery company, which engages in the development of therapeutics and vaccines. The firm designs, tests, and manufactures adenoviral-based product candidates using its proprietary AdenoVerse platform. Its products include CGF166-Hearing Loss; GV2311-RSV Vaccine; and GV2207-HSV-2 Immunotherapeutic. The company was founded in December 1992 and is headquartered in Gaithersburg, MD.